Get the Daily Brief
Latest Biotech News
AbbVie pays $100M upfront to option Zejing’s DLL3 trispecific
AbbVie signed an option‑to‑license agreement with Zejing Biopharmaceutical for alveltamig (ZG006), a trispecific T‑cell engager targeting DLL3. AbbVie will pay $100 million upfront for global...
Servier taps Insilico’s AI platform — multiyear oncology pact worth up to near‑term millions
Servier entered a multiyear research and development collaboration with Insilico Medicine to leverage the Pharma.AI platform for oncology target discovery and early development. Insilico will...
Comanche secures $40M to advance first‑in‑class preeclampsia siRNA into clinic
Comanche Biopharma raised an additional $40 million to fund human testing of its investigational siRNA injectable for preeclampsia, aiming to move the program into multiple clinical sites. The...
Psithera spins out of Roivant with $47.5M — targets immune and inflammatory diseases
Psithera Inc., formerly Psivant Therapeutics, completed a spin‑out from Roivant and announced a $47.5 million Series A to fund immune and inflammatory disease programs. The Watertown, Mass....
Cas3 deletes mutant TTR in vivo — new off-target assay tightens safety
Researchers demonstrated CRISPR–Cas3 can generate long-range deletions at the TTR locus and substantially lower circulating transthyretin in mice, offering an alternative to Cas9 strategies for...
Inhalable exosomes deliver bispecific T‑cell activator — fights ICI‑resistant melanoma
An engineered inhalable exosome platform delivered a bispecific T‑cell activator to pembrolizumab‑resistant metastatic melanoma in preclinical models, reactivating tumor‑infiltrating T cells and...
CONCORD unifies single‑cell landscapes across studies
A new contrastive learning framework, CONCORD, produced denoised, batch‑integrated cell representations that preserve differentiation trajectories and other biological structures across diverse...
SPLISOSM pins down isoforms in space — new spatial transcriptomics tool
Researchers published SPLISOSM, a method to map isoform usage and regulatory mechanisms from spatial transcriptomics data. The tool increases statistical power to detect differential isoform...
AI and experiments resolve RNA structure — integrated toolkit published
A Nature Biotechnology perspective and accompanying work outlined integrated experimental and AI workflows for RNA structure determination, combining high‑throughput chemical probing with machine...
AbbVie pays $100M upfront for Zejing DLL3 candidate — deal could top $1.07B
AbbVie signed an option‑to‑license agreement with Zejing Biopharmaceutical for alveltamig (ZG006), a trispecific T‑cell engager targeting DLL3; AbbVie paid $100 million upfront and could pay an...
Comanche raises $40M to push preeclampsia siRNA into human trials
Comanche Biopharma secured $40 million in new capital to advance its experimental siRNA injectable intended as the potential first therapy for preeclampsia into human testing. The funding will...
Big pharma doubles down on AI discovery: Sanofi and Servier deals land
Sanofi agreed a collaboration with AI biotech Earendil Labs worth $160 million upfront and near‑term to discover multiple bispecific autoimmune programs, with potential milestones lifting the deal...
Wegovy pill lands in US — pricing, employer coverage headaches loom
Novo Nordisk launched the oral formulation of Wegovy in the U.S., listing insured patient copays as low as $25 per month and a $149 cash price. The company positioned the pill to broaden access to...
Setrusumab fails Phase III fracture endpoints — Ultragenyx and Mereo plan cuts
Ultragenyx and Mereo reported that setrusumab, an anti‑sclerostin antibody for osteogenesis imperfecta, missed primary fracture‑rate endpoints in the Phase III portions of the Orbit and Cosmic...
Novo Nordisk launches Wegovy pill: $25 insured, $149 cash
Novo Nordisk launched an oral formulation of its obesity drug Wegovy in the US, setting insured patient co-pay as low as $25 per month and a $149 cash price. The company disclosed the pricing...
Setrusumab misses primary endpoints: Ultragenyx, Mereo to cut costs
Ultragenyx and Mereo said setrusumab failed to meet primary endpoints in two late‑phase trials for brittle bone disease (osteogenesis imperfecta), missing statistically significant reductions in...
St. Jude publishes assay to detect base-editor off-targets – improves safety screening
St. Jude Children’s Research Hospital released a new method to detect small off‑target genome changes from base editors, the team said. The approach aims to make precision genome‑editing safety...
Optimized AAV9 improves safety, efficacy in SMARD1 models
Researchers reported optimization efforts for AAV9‑based gene therapy targeting SMARD1 (spinal muscular atrophy with respiratory distress 1) and related CMT2S models, detailing adjustments that...
11‑amino‑acid peptide thwarts CRC immune evasion: Cell Research
A study published in Cell Research described an engineered 11‑amino‑acid peptide that targets PTPN13 and the C‑terminal region of APC to block colorectal cancer (CRC) mechanisms that enable immune...
Romosozumab outperforms PTH analogs — fracture reduction evidence mounts
Two recent reports compared romosozumab, an anti‑sclerostin monoclonal antibody, with parathyroid hormone (PTH 1–34) analogs for preventing osteoporotic fractures in women. Authors found...